Pipeline

January 14, 2019

Company	Drug/Device	Medical Condition	Status
Oppilan Pharma Ltd.	OPL-002	inflammatory bowel disease (IBD)	Phase I trial initiated enrolling 72 subjects
Pliant Therapeutics, Inc.	PLN-74809	idiopathic pulmonary fibrosis	Phase I trial initiated enrolling 90 healthy subjects
Deciphera Pharmaceuticals, Inc.	rebastinib in combination with carboplatin	advanced or metastatic solid tumors	Phase Ib/II trial initiated enrolling 117 subjects (18 subjects in Part 1 and 99 subjects in Part 2)
Protagonist Therapeutics, Inc.	PTG-300	beta thalassemia	Phase II trial initiated enrolling 84 adolescent and adult subjects
Galapagos NV	GLPG1690	systemic sclerosis (SSc, or scleroderma)	Phase IIa trial initiated enrolling 30 subjects with diffuse cutaneous SSc
Urovant Sciences	vibegron	abdominal pain due to irritable bowel syndrome (IBS)	Phase IIa trial initiated enrolling 200 female subjects
Seres Therapeutics, Inc.	SER-287	active mild-to-moderate ulcerative colitis	Phase IIb trial initiated enrolling 200 subjects
Pfizer, Inc.	PF-06651600	moderate to severe alopecia areata	Phase IIb/III trial initiated enrolling 660 subjects
NeuroBo Pharmaceuticals, Inc.	NB-01	diabetic neuropathic pain	Phase III trial initiated enrolling 717 adult subjects at 80 sites in the U.S.
Tivic Health Systems, Inc.	ClearUP	sinus pain due to allergic rhinitis (hay fever)	510(k) clearance granted by the FDA
StemCyte	Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001)	spinal cord injury	IND approval granted by the FDA
MicroVention, Inc.	WEB Aneurysm Embolization System	intracranial wide neck bifurcation aneurysms	PMA approval granted by the FDA
Rainier Therapeutics, Inc.	vofatamab	advanced or metastatic urothelial cell carcinoma (bladder cancer) that is positive for FGFR3 mutation and/or fusion	Fast Track Designation granted by the FDA
Grifols	Erytra Eflexis	blood grouping	Approval granted by the FDA